[1] Blechacz B. Cholangiocarcinoma: Current Knowledge and New Developments[J]. Gut Liver, 2017, 11(1): 13-26.
[2] Chan E, Berlin J. Biliary tract cancers: understudied and poorly understood[J]. J Clin Oncol, 2015, 33(16): 1845-8.
[3] Tyson G L, El-Serag H B. Risk factors for cholangiocarcinoma[J]. Hepatology, 2011, 54(1): 173-84.
[4] Razumilava N, Gores G J. Cholangiocarcinoma[J]. Lancet, 2014, 383(9935): 2168-79.
[5] Rizvi S, Gores G J. Pathogenesis, diagnosis, and management of cholangiocarcinoma[J]. Gastroenterology, 2013, 145(6): 1215-29.
[6] Patel A H, Harnois D M, Klee G G, et al. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis[J]. Am J Gastroenterol, 2000, 95(1): 204-7.
[7] Blechacz B, Gores G J. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment[J]. Hepatology, 2008, 48(1): 308-21.
[8] Doherty B, Nambudiri V E, Palmer W C. Update on the Diagnosis and Treatment of Cholangiocarcinoma[J]. Curr Gastroenterol Rep, 2017, 19(1): 2.
[9] Macias R I R, Banales J M, Sangro B, et al. The search for novel diagnostic and prognostic biomarkers in cholangiocarcinoma[J]. Biochim Biophys Acta Mol Basis Dis, 2018, 1864(4 Pt B): 1468-1477.
[10] Kulasingam V, Diamandis E P. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies[J]. Nat Clin Pract Oncol, 2008, 5(10): 588-99.
[11] Nones K, Patch A M. The Impact of Next Generation Sequencing in Cancer Research[J]. Cancers (Basel), 2020, 12(10).
[12] Chan-On W, Nairismägi M L, Ong C K, et al. Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers[J]. Nat Genet, 2013, 45(12): 1474-8.
[13] Zou S, Li J, Zhou H, et al. Mutational landscape of intrahepatic cholangiocarcinoma[J]. Nat Commun, 2014, 5: 5696.
[14] Borger D R, Tanabe K K, Fan K C, et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping[J]. Oncologist, 2012, 17(1): 72-9.
[15] Zhang X, Miao R, Liu T, et al. IDH1 as a frequently mutated gene has potential effect on exosomes releasement by epigenetically regulating P2RX7 in intrahepatic cholangiocarcinoma[J]. Biomed Pharmacother, 2019, 113: 108774.
[16] Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis[J]. BMC Bioinformatics, 2008, 9: 559.
[17] Yu G, Wang L G, Han Y, et al. clusterProfiler: an R package for comparing biological themes among gene clusters[J]. Omics, 2012, 16(5): 284-7.
[18] Szklarczyk D, Gable A L, Lyon D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets[J]. Nucleic Acids Res, 2019, 47(D1): D607-d613.
[19] Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks[J]. Genome Res, 2003, 13(11): 2498-504.
[20] Bader G D, Hogue C W. An automated method for finding molecular complexes in large protein interaction networks[J]. BMC Bioinformatics, 2003, 4: 2.
[21] Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses[J]. Nucleic Acids Res, 2017, 45(W1): W98-w102.
[22] Li T, Fan J, Wang B, et al. TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells[J]. Cancer Res, 2017, 77(21): e108-e110.
[23] Torre L A, Bray F, Siegel R L, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2): 87-108.
[24] Blechacz B, Komuta M, Roskams T, et al. Clinical diagnosis and staging of cholangiocarcinoma[J]. Nat Rev Gastroenterol Hepatol, 2011, 8(9): 512-22.
[25] Turgeon M K, Maithel S K. Cholangiocarcinoma: a site-specific update on the current state of surgical management and multi-modality therapy[J]. Chin Clin Oncol, 2020, 9(1): 4.
[26] Zhang S, Tischer T. Cyclin A2 degradation during the spindle assembly checkpoint requires multiple binding modes to the APC/C[J], 2019, 10(1): 3863.
[27] Nam H J, Van Deursen J M. Cyclin B2 and p53 control proper timing of centrosome separation[J]. Nat Cell Biol, 2014, 16(6): 538-49.
[28] Cooper W A, Kohonen-Corish M R, Mccaughan B, et al. Expression and prognostic significance of cyclin B1 and cyclin A in non-small cell lung cancer[J]. Histopathology, 2009, 55(1): 28-36.
[29] Nozoe T, Inutsuka S, Honda M, et al. Clinicopathologic significance of cyclin A expression in colorectal carcinoma[J]. J Exp Clin Cancer Res, 2004, 23(1): 127-33.
[30] Lee Y, Lee C E, Oh S. Pharmacogenomic Analysis Reveals CCNA2 as a Predictive Biomarker of Sensitivity to Polo-Like Kinase I Inhibitor in Gastric Cancer[J], 2020, 12(6).
[31] Li R, Jiang X, Zhang Y, et al. Cyclin B2 Overexpression in Human Hepatocellular Carcinoma is Associated with Poor Prognosis[J]. Arch Med Res, 2019, 50(1): 10-17.
[32] Qian X, Song X, He Y, et al. CCNB2 overexpression is a poor prognostic biomarker in Chinese NSCLC patients[J]. Biomed Pharmacother, 2015, 74: 222-7.
[33] Lei C Y, Wang W, Zhu Y T, et al. The decrease of cyclin B2 expression inhibits invasion and metastasis of bladder cancer[J]. Urol Oncol, 2016, 34(5): 237.e1-10.
[34] Kapanidou M, Curtis N L, Bolanos-Garcia V M. Cdc20: At the Crossroads between Chromosome Segregation and Mitotic Exit[J]. Trends Biochem Sci, 2017, 42(3): 193-205.
[35] Schrock M S, Stromberg B R, Scarberry L, et al. APC/C ubiquitin ligase: Functions and mechanisms in tumorigenesis[J]. Semin Cancer Biol, 2020.
[36] Wang Z, Wan L, Zhong J, et al. Cdc20: a potential novel therapeutic target for cancer treatment[J]. Curr Pharm Des, 2013, 19(18): 3210-4.
[37] Wang L, Zhang J, Wan L, et al. Targeting Cdc20 as a novel cancer therapeutic strategy[J]. Pharmacol Ther, 2015, 151: 141-51.
[38] Li B, Xu W W, Guan X Y, et al. Competitive Binding Between Id1 and E2F1 to Cdc20 Regulates E2F1 Degradation and Thymidylate Synthase Expression to Promote Esophageal Cancer Chemoresistance[J]. Clin Cancer Res, 2016, 22(5): 1243-55.
[39] Mao D D, Gujar A D, Mahlokozera T, et al. A CDC20-APC/SOX2 Signaling Axis Regulates Human Glioblastoma Stem-like Cells[J]. Cell Rep, 2015, 11(11): 1809-21.
[40] Shi M, Dai W Q, Jia R R, et al. APC(CDC20)-mediated degradation of PHD3 stabilizes HIF-1a and promotes tumorigenesis in hepatocellular carcinoma[J]. Cancer Lett, 2020, 496: 144-155.
[41] Guo J, Wu Y, Du J, et al. Deregulation of UBE2C-mediated autophagy repression aggravates NSCLC progression[J]. Oncogenesis, 2018, 7(6): 49.
[42] Kim Y J, Lee G, Han J, et al. UBE2C Overexpression Aggravates Patient Outcome by Promoting Estrogen-Dependent/Independent Cell Proliferation in Early Hormone Receptor-Positive and HER2-Negative Breast Cancer[J]. Front Oncol, 2019, 9: 1574.
[43] Bajaj S, Alam S K, Roy K S, et al. E2 Ubiquitin-conjugating Enzyme, UBE2C Gene, Is Reciprocally Regulated by Wild-type and Gain-of-Function Mutant p53[J]. J Biol Chem, 2016, 291(27): 14231-47.
[44] Potkonjak M, Miura J T, Turaga K K, et al. Intrahepatic cholangiocarcinoma and gallbladder cancer: distinguishing molecular profiles to guide potential therapy[J]. HPB (Oxford), 2015, 17(12): 1119-23.
[45] Delgado J L, Hsieh C M, Chan N L, et al. Topoisomerases as anticancer targets[J]. Biochem J, 2018, 475(2): 373-398.
[46] Hiasa H. DNA Topoisomerases as Targets for Antibacterial Agents[J]. Methods Mol Biol, 2018, 1703: 47-62.
[47] Glover D M, Leibowitz M H, Mclean D A, et al. Mutations in aurora prevent centrosome separation leading to the formation of monopolar spindles[J]. Cell, 1995, 81(1): 95-105.
[48] Maia A R, Van Heesbeen R G, Medema R H. A growing role for Aurora A in chromosome instability[J]. Nat Cell Biol, 2014, 16(8): 739-41.
[49] Goldenson B, Crispino J D. The aurora kinases in cell cycle and leukemia[J]. Oncogene, 2015, 34(5): 537-45.
[50] Ding X, Huang T, Peng C, et al. Therapeutic Rationale to Target Highly Expressed Aurora kinase A Conferring Poor Prognosis in Cholangiocarcinoma[J]. J Cancer, 2020, 11(8): 2241-2251.
[51] Raemaekers T, Ribbeck K, Beaudouin J, et al. NuSAP, a novel microtubule-associated protein involved in mitotic spindle organization[J]. J Cell Biol, 2003, 162(6): 1017-29.
[52] Li C, Xue C, Yang Q, et al. NuSAP governs chromosome oscillation by facilitating the Kid-generated polar ejection force[J]. Nat Commun, 2016, 7: 10597.
[53] Li H, Zhang W, Yan M, et al. Nucleolar and spindle associated protein 1 promotes metastasis of cervical carcinoma cells by activating Wnt/β-catenin signaling[J]. J Exp Clin Cancer Res, 2019, 38(1): 33.
[54] Xu Z, Wang Y, Xiong J, et al. NUSAP1 knockdown inhibits cell growth and metastasis of non-small-cell lung cancer through regulating BTG2/PI3K/Akt signaling[J], 2020, 235(4): 3886-3893.
[55] Wang H, Wang L, Erdjument-Bromage H, et al. Role of histone H2A ubiquitination in Polycomb silencing[J]. Nature, 2004, 431(7010): 873-8.
[56] Su W, Han H H, Wang Y, et al. The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating Stemness and Immune Suppression[J]. Cancer Cell, 2019, 36(2): 139-155.e10.
[57] Tong Y, Eigler T. Transcriptional targets for pituitary tumor-transforming gene-1[J]. J Mol Endocrinol, 2009, 43(5): 179-85.
[58] Yoon C H, Kim M J, Lee H, et al. PTTG1 oncogene promotes tumor malignancy via epithelial to mesenchymal transition and expansion of cancer stem cell population[J]. J Biol Chem, 2012, 287(23): 19516-27.
[59] Chen R, Duan J, Li L, et al. mTOR promotes pituitary tumor development through activation of PTTG1[J]. Oncogene, 2017, 36(7): 979-988.
[60] Ishimi Y, Komamura-Kohno Y, Kwon H J, et al. Identification of MCM4 as a target of the DNA replication block checkpoint system[J]. J Biol Chem, 2003, 278(27): 24644-50.
[61] Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm[J]. Nat Rev Cancer, 2009, 9(3): 153-66.
[62] Briggs C D, Neal C P, Mann C D, et al. Prognostic molecular markers in cholangiocarcinoma: a systematic review[J]. Eur J Cancer, 2009, 45(1): 33-47.
[63] Chen J, Song W, Du Y, et al. Inhibition of KLHL21 prevents cholangiocarcinoma progression through regulating cell proliferation and motility, arresting cell cycle and reducing Erk activation[J]. Biochem Biophys Res Commun, 2018, 499(3): 433-440.
[64] Samukawa E, Fujihara S, Oura K, et al. Angiotensin receptor blocker telmisartan inhibits cell proliferation and tumor growth of cholangiocarcinoma through cell cycle arrest[J]. Int J Oncol, 2017, 51(6): 1674-1684.
[65] Ke F, Wang Z, Song X, et al. Cryptotanshinone induces cell cycle arrest and apoptosis through the JAK2/STAT3 and PI3K/Akt/NFκB pathways in cholangiocarcinoma cells[J]. Drug Des Devel Ther, 2017, 11: 1753-1766.
[66] Augustine M M, Fong Y. Epidemiology and risk factors of biliary tract and primary liver tumors[J]. Surg Oncol Clin N Am, 2014, 23(2): 171-88.
[67] Mao Z Y, Zhu G Q, Xiong M, et al. Prognostic value of neutrophil distribution in cholangiocarcinoma[J]. World J Gastroenterol, 2015, 21(16): 4961-8.
[68] Solinas G, Germano G, Mantovani A, et al. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation[J]. J Leukoc Biol, 2009, 86(5): 1065-73.
[69] Prakobwong S, Yongvanit P, Hiraku Y, et al. Involvement of MMP-9 in peribiliary fibrosis and cholangiocarcinogenesis via Rac1-dependent DNA damage in a hamster model[J]. Int J Cancer, 2010, 127(11): 2576-87.
[70] Hasita H, Komohara Y, Okabe H, et al. Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma[J]. Cancer Sci, 2010, 101(8): 1913-9.
[71] Kitano Y, Okabe H, Yamashita Y I, et al. Tumour-infiltrating inflammatory and immune cells in patients with extrahepatic cholangiocarcinoma[J]. Br J Cancer, 2018, 118(2): 171-180.
[72] Takagi S, Miyagawa S, Ichikawa E, et al. Dendritic cells, T-cell infiltration, and Grp94 expression in cholangiocellular carcinoma[J]. Hum Pathol, 2004, 35(7): 881-6.
[73] Goeppert B, Frauenschuh L, Zucknick M, et al. Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer[J]. Br J Cancer, 2013, 109(10): 2665-74.
[74] Kasper H U, Drebber U, Stippel D L, et al. Liver tumor infiltrating lymphocytes: comparison of hepatocellular and cholangiolar carcinoma[J]. World J Gastroenterol, 2009, 15(40): 5053-7.